SCHEMBL5544762

SCHEMBL5544762

CC(C)(C)c1ccc(N([C]=O)Cc2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 2/20 0.48
RAB9A P51151 3/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
PTGES O14684 2/20 0.44
ALOX5 P09917 2/20 0.44
SIGMAR1 Q99720 2/20 0.42
TMEM97 Q5BJF2 1/20 0.42
LMNA P02545 2/20 0.42
NR1H2 P55055 4/20 0.40
NR1H3 Q13133 4/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP2C19 P33261 1/20 0.39
CYP2D6 P10635 2/20 0.38
NR1I2 O75469 1/20 0.38
ADRA2A P08913 1/20 0.38
ACHE P22303 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2A P28223 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2096287 0.84 MTOR (0.46) MEN1KMT2APTGESSIGMAR1TMEM97
SCHEMBL305633 0.82 TSHR (0.45) RAB9AMEN1KMT2ALMNANPC1
SCHEMBL2093212 0.81 CYP2C19 (0.59) LMNAALDH1A1CYP2C19
SCHEMBL5541684 0.80 TP53 (0.48) MEN1KMT2ALMNAALDH1A1CYP2C19
SCHEMBL2094147 0.78 CNR1 (0.43) MEN1KMT2ASIGMAR1TMEM97CYP2C19
SCHEMBL2091209 0.78 L3MBTL1 (0.43) RAB9AMEN1KMT2ASIGMAR1TMEM97
SCHEMBL2085584 0.78 KCNA5 (0.44) MEN1KMT2AKCNH2
SCHEMBL2096014 0.78 HTR2A (0.40) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL27787417 0.78 MAOB (0.44) RAB9AMEN1KMT2ANPC1ALDH1A1
SCHEMBL10296030 0.78 CYP2C19 (0.63) NR1H4RAB9AMEN1KMT2APTGES

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NR1H4 171/4885RAB9A 2824/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.